期刊文献+

5-氨基水杨酸肠溶定时释放片的制备和溶出度研究 被引量:8

Preparation of 5-aminosalicylic acid enteric time-controlled released tablets and study on their dissolution
下载PDF
导出
摘要 目的 制备 5 氨基水杨酸 ( 5 ASA)肠溶包衣片 ,使药物在结肠释放。方法 以崩解时限为指标 ,用正交试验筛选片芯的处方 ,考察了压力和硬脂酸镁含量对片芯的影响。根据溶出度试验 ,以包衣片在 pH6.8的磷酸盐缓冲液中释放 1 0 %的时间t0 .1为指标 ,用均匀设计筛选并优化包衣液的处方 ,同时考察了包衣量对溶出曲线和t0 .1的影响 ,以及包衣液的动力黏度对t0 .1的影响。结果 以 3 %的羧甲基淀粉钠 (DST)和 1 0 %的PVP醇溶液为黏合剂所制的片芯崩解快 ;丙烯酸树脂EudragitS1 0 0、乙基纤维素及癸二酸二丁酯组成的包衣液是影响t0 .1的主要因素 ,三者的量在 1 0 0mL中为 9,1 .5,1mL时 ,t0 .1为1 77min。结论 采用合适的片芯和包衣 ,可制备 5 氨基水杨酸肠溶定时释放片。 OBJECTIVE: To prepare the 5-aminosalicylic acid (5-ASA) enteric time-controlled released tablets with site-specific drug delivery in colon. METHODS: The disintegration time was used to evaluate the formulation of the core by orthogonal design. The effects of tableting pressure and the content of magnesium stearate on the core were investigated. According to the release process test, the lag time that the drug release up to 10% taken in pH6.8 phosphate buffer was used to evaluate the formulation of the coating solution by uniform design. The effects on the drug release profile and t0.1 by the amount of coating and t0.1 by kinetic viscosity were investigated. RESULTS: Sodium carboxymethyl starch (CMS-Na, DST) at 3% and concentration of PVP as binding agent at 10% in alcoholic solution produced desirable disintegrating time of the core. The coating solution consisted of Eudragit S100, ethyl cellulose and dibutyl sebacate was the important factor to t0.1&middot t0.1 of the optimized formulation was 177 min when the amount of above three components were 9,1.5 and 1 mL, respectively, in 100 mL solution. CONCLUSION: 5-ASA Enteric time-controlled released tablets can be prepared by using adequate core and coating.
出处 《中国药学杂志》 EI CAS CSCD 北大核心 2001年第10期673-677,共5页 Chinese Pharmaceutical Journal
关键词 5-氨基水杨酸 PH敏感 定时释放 结肠 片剂 Controlled drug delivery Dissolution Organic acids Pharmacokinetics Viscosity
  • 相关文献

参考文献1

二级参考文献1

  • 1Dr. Giuseppe d’Albasio M.D.,Giacomo Trallori M.D.,Augusto Ghetti M.D.,Monica Milla M.D.,Andrea Nucci M.D.,Franco Pacini M.D.,Antonio Morettini M.D.. Intermittent therapy with high-dose 5-aminosalicylic acid enemas for maintaining remission in ulcerative proctosigmoiditis[J] 1990,Diseases of the Colon & Rectum(5):394~397

共引文献5

同被引文献49

  • 1邱雪兰,杨明,谢兴亮.口服结肠靶向给药系统中的辅料[J].中国药业,2005,14(1):21-22. 被引量:4
  • 2闫金红,张翠萍,杨频.羟丙基-β-环糊精与丹参酮IIA包合作用的研究[J].化学学报,2006,64(7):652-656. 被引量:16
  • 3曾启华,王娅,祝黔江,薛赛凤,牟兰,陶朱.七、八元瓜环对萘二胺异构体相互作用的考察[J].化学学报,2006,64(10):1085-1092. 被引量:11
  • 4张焱,陈庆华.红霉素肠溶微丸及其特性研究[J].中国医药工业杂志,1996,27(10):448-451. 被引量:20
  • 5Michailova V, TitevaS, Kotsilkova R, et al. Water uptake and relaxation processes in mixed unlimited swelling hydrogels[J]. Int J Pharm, 2000, 209(1-2) : 45-56.
  • 6Yung YJ, Lee JS, Kim YM, et al. Synthesis and in vitro/in vivo evaluation of 5-aminosalicyl-Glycine as a colon-specific prodrug of 5-aminosalicylic acid[J]. J Pharm Sci, 2000, 89(5): 594-602.
  • 7Benbow AG, Gould I. Mesalazine preparations [J]. Lancet, 1998,351(3): 68-9.
  • 8Richard NF, Barbara H, Lonmie R, et al. Colonic delivery ofdexamethasone from a prodrug accelerates healing of colitis in rats without adrenal suppression[J]. Gastroenterology, 1995, 108(9): 1688-99.
  • 9Tozaki H, Nishioka J, Komoike J, et al. Enhanced absorption of insulin and (Asu1,7) eel-calcitonin using novel azopolymer-coated pellets for colon-specific drug delivery[J]. J Pharm Sci, 2001, 90(1): 89-97.
  • 10Tozaki H, Fujita T, Odoriba T, et al. Colon-specific delivery of R68070, a new thromboxane synthase inhibitor, using chitosan capsules: therapeutic effects against 2, 4, 6-trinitrobenzene sulfonic acid-induced ulcerative colitis in rats [J]. Life Sci, 1999, 64(b):1155-62.

引证文献8

二级引证文献65

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部